ata
fig
heterogen
mixtur
polym
form
salicyl
acid
treat
formaldehyd
sulfur
acid
sodium
ata
often
incorrectli
repres
triphenylmethan
dye
fig
rather
polym
fig
ata
known
long
time
interact
number
enzym
includ
dna
polymeras
rna
polymeras
revers
transcriptas
dna
polymeras
synthetas
ribonucleotid
reductas
ribonucleas
review
cushman
et
consid
nonspecif
enzym
simpli
ata
polycarboxyl
would
bind
electrostat
interact
protein
contain
posit
charg
residu
use
ata
inhibitor
nucleas
nucleic
isol
advoc
certain
interest
ata
reviv
shown
inhibit
cytopathogen
hiv
cell
ata
shown
specif
interact
cell
princip
receptor
hiv
select
prevent
bind
monoclon
antibodi
cell
studi
ata
also
appear
block
bind
monoclon
antibodi
viral
envelop
glycoprotein
lower
molecular
weight
fraction
ata
bound
prevent
cytopath
could
conclud
ata
fraction
bound
avidli
bind
ata
absenc
bind
suffici
number
ata
monom
analogu
triphenylcarbinol
triphenylmethan
proven
virtual
inact
interest
ata
potenti
lead
compound
treatment
hiv
infect
larg
wane
yet
new
virus
emerg
interest
ata
ata
report
potent
inhibitor
sar
ata
predict
use
analysi
bind
inhibit
sar
cov
rna
polymeras
rdrp
therebi
block
viral
howev
whether
ata
inhibit
sar
cov
replic
interfer
rdrp
function
directli
demonstr
consid
neg
charg
ata
one
could
inde
question
easili
compound
enter
cell
follow
report
ata
inhibit
earli
stage
vaccinia
viru
result
two
mechan
action
block
extracellular
kinas
erk
phosphoryl
activ
erk
cascad
essenti
vaccinia
viru
replic
ii
inhibit
phosphatas
activ
viral
enzym
play
essenti
role
initi
viral
earli
gene
transcript
fact
ata
would
abl
interfer
variou
signal
pathway
viz
erk
signal
growth
factor
signal
given
current
interest
new
therapeut
batteri
approxim
structur
divers
compound
screen
ata
emerg
one
promis
although
ata
origin
assum
inhibit
influenza
viru
replic
inhibit
influenza
viral
polymeras
rdrp
hung
et
found
ata
inhibit
influenza
polymeras
instead
interf
viral
neuraminidas
compet
sialic
acid
although
ata
structur
distinct
sialic
acid
enzym
substrat
bind
site
least
suggest
molecular
model
anoth
viru
accompani
viral
target
receiv
increas
attent
sam
methyltransferas
mtase
associ
flavivirus
ie
dengu
viru
ata
identifi
result
combin
comput
experiment
screen
approach
potent
flavivir
mtase
inhibitor
even
potent
known
date
accord
milani
et
thu
shortag
potenti
therapeut
applic
ata
separ
eventu
therapeut
use
resolv
case
whether
propos
molecular
target
despit
molecular
dock
comput
realli
account
observ
antivir
activ
given
myriad
possibl
interact
site
ata
repres
one
mani
site
compound
could
theoret
interact
follow
ata
lead
see
supra
seri
stori
mark
cushman
collabor
describ
cosalan
fig
conceptu
consid
ata
deriv
miss
one
salicyl
acid
part
conjug
cholestan
compound
act
primarili
inhibit
viral
cholestan
part
respons
anchor
compound
cell
membran
cholestan
develop
properti
remain
unclear
instead
open
way
adam
deriv
potenti
nnrti
thu
join
wide
array
nnrti
hept
tibo
nevirapin
bhap
tsao
etc
describ
adam
deriv
begin
recogn
genuin
nnrti
exampl
suggest
methoxycarbonyl
compound
cushman
et
compound
cushman
et
fig
although
structur
littl
resembl
could
observ
classic
nnrti
hept
tibo
adam
particularli
regard
paradigmat
butterfli
structur
assign
nnrti
start
origin
adam
new
adam
deriv
optim
exhibit
select
index
ie
methoxycarbonyl
potenc
even
increas
select
increas
chlorin
replac
bromin
methoxycarbonyl
fig
synthesi
adam
describ
xu
et
improv
potenc
especi
nnrti
resist
mutat
ie
note
adam
deriv
base
ethyl
instead
methyl
fig
latter
compound
time
year
consid
promis
adam
new
method
mean
time
devis
prepar
new
adam
deriv
nonident
aromat
potenti
therapeut
use
adam
could
compris
metabol
instabl
may
expect
ester
moieti
like
hydrolyz
nonspecif
esteras
present
human
therefor
structur
modif
ie
thioester
introduc
parent
compound
fig
compound
fig
result
enhanc
stabil
min
diminish
cytotox
maintain
reason
potenc
similarli
modif
compound
fig
includ
introduct
benzo
isoxazol
compound
fig
enhanc
stabil
min
diminish
cytotox
maintain
moder
antivir
potenc
benzoxazolyl
deriv
e
acid
methyl
ester
compound
fig
valu
nm
rf
iiib
strain
z
e
fluorid
compound
accompani
enhanc
metabol
stabil
rat
plasma
hr
present
promis
compound
within
adam
seri
compound
z
acid
methyl
ester
fig
valu
nm
rf
nm
iiib
primari
object
optim
adam
replac
metabol
unstabl
methyl
ester
moieti
stabl
isoster
ie
benzo
isoxazol
maintain
enhanc
antivir
potenc
adam
potenti
drug
howev
potenti
applic
adam
ignor
may
much
potenti
inhibitor
phosphodiesteras
belong
phosphodiesteras
famili
hydrolas
respons
regul
cellular
camp
level
play
role
hiv
infect
specif
involv
inflamm
weak
activ
howev
two
distantli
relat
adam
deriv
ie
compound
like
colchicin
prove
activ
tubulin
polymer
inhibitor
respect
make
worth
pursu
potenti
anticanc
drug
candid
exactli
year
discoveri
hiv
caus
agent
aid
nobel
prize
medicin
physiolog
mikula
popov
compound
offici
approv
treatment
recent
compound
complet
drug
armamentarium
present
one
raltegravir
soon
expect
two
raltegravir
elvitegravir
raltegravir
plu
optim
background
therapi
provid
better
viral
suppress
optim
background
therapi
alon
least
raltegravir
consid
valuabl
addit
current
armamentarium
treatment
patient
infect
era
ini
start
daria
hazuda
paper
inhibitori
effect
diketo
acid
ie
integr
replic
hiv
cell
cultur
provid
first
proof
concept
integras
specif
strand
transfer
inhibitor
act
antivir
agent
first
demonstr
proof
principl
extend
variou
relat
compound
ie
naphthyridin
carboxamid
prove
efficaci
vivo
retrovir
immunodefici
viru
replic
vivo
rhesu
macaqu
henc
come
surpris
compound
carbamoyl
ethyl
raltegravir
fig
select
clinic
candid
final
becam
licens
clinic
use
first
ini
ever
approv
treatment
hiv
infect
meanwhil
advoc
microbicid
prevent
hiv
ini
ever
use
topic
microbicid
preferenti
combin
rule
system
use
well
class
hiv
inhibitor
includ
revers
transcriptas
inhibitor
viral
entri
inhibitor
ini
licens
clinic
use
elvitegravir
fig
raltegravir
current
dose
mg
twice
daili
elvitegravir
dose
daili
mg
current
combin
mg
ritonavir
booster
horizon
howev
combin
elvitegravir
gilead
booster
pharmacoenhanc
gs
truvada
tenofovir
disoproxil
fumar
emtricitabin
togeth
make
one
pill
treatment
tent
call
quad
consist
four
compound
structur
elvitegravir
fig
built
upon
quinolon
acid
scaffold
pharmacophor
also
serv
start
point
design
second
gener
ini
quinolon
fluoroquinolon
known
transcript
inhibitor
therefor
interest
ascertain
whether
elvitegravir
diketo
acid
quinolon
behav
ini
transcript
inhibitor
unlik
like
elvitegravir
behav
genuin
elvitegravir
potent
ini
mechan
action
ie
inhibit
strand
transfer
function
integras
must
similar
drug
exhibit
parallel
resist
profil
k
mutat
confer
highest
resist
addit
k
mutat
mutat
ie
shown
confer
resist
elvitegravir
examin
ini
ie
raltegravir
one
hand
clinic
relev
mutat
remain
demonstr
ie
regard
possibl
reduc
fit
viral
mutant
hand
help
gain
insight
mode
action
ini
eventu
facilit
design
new
ini
ledgf
stori
start
peter
cherepanov
demonstr
use
synthet
gene
effici
express
integras
achiev
human
cell
cherepanov
et
al
found
nuclei
human
cell
stabli
express
hiv
integras
form
stabl
tetram
associ
protein
implic
regul
gene
express
cellular
stress
moreov
ledgf
found
robustli
enhanc
strand
transfer
activ
hiv
integras
vitro
cherepanov
et
conclud
ledgf
may
constitut
novel
target
drug
therapi
subsequ
studi
shown
account
karyophil
ie
nuclear
target
chromosom
target
essenti
hiv
dna
integr
chromosom
first
exampl
cellular
protein
control
locat
hiv
integr
human
fact
abl
interact
differ
lentivir
integras
includ
bovin
immunodefici
viru
viru
equin
infecti
anemia
viru
nonlentivir
integras
deltaretrovirus
spumavirus
possess
detect
affin
poeschla
thu
conclud
may
act
chromatin
dock
factor
receptor
lentivir
preintegr
complex
tether
hiv
integras
chromatin
protect
degrad
strongli
influenc
pattern
hiv
given
fact
ubiquit
nuclear
protein
tightli
associ
chromatin
throughout
cell
cycl
although
import
strictli
essenti
cofactor
lentivir
dna
could
ubiquit
protein
strictli
essenti
retrovir
dna
integr
serv
target
develop
novel
class
antiretrovir
drug
ledgf
per
se
interact
integras
thu
interact
ppi
illustr
figur
may
serv
potenti
target
drug
discoveri
therefor
sever
issu
target
valid
import
replic
ii
inhibit
specif
ppi
associ
toxic
iii
structur
inform
ppi
avail
iv
identif
genuin
inhibitor
provid
ultim
pursuit
ledgf
potenti
target
drug
may
seem
sisyphian
task
take
account
ppi
interact
integras
ccd
ledgf
ibd
fig
also
role
ppi
fulfil
integr
provir
dna
target
chromosom
dna
make
stricto
sensu
menag
quatr
tantal
perspect
deter
sever
investig
launch
search
small
molecul
ppi
inhibitor
alreadi
nicknam
smppii
screen
inhibitor
hiv
interact
luminesc
proxim
first
appar
success
alreadi
report
benzoic
acid
deriv
fig
would
function
novel
inhibitor
target
interact
integras
ccd
ledgf
shown
figur
would
princip
interact
cdd
domain
integras
approach
open
wealth
possibl
ie
relationship
sar
studi
pharmacokinet
toxic
particularli
confirmatori
studi
valid
presum
target
action
provid
ultim
put
forward
frederick
new
antivir
agent
treatment
influenza
urgent
need
one
limit
current
drug
ie
oseltamivir
emerg
resist
among
influenza
strain
fear
may
also
emerg
among
avian
influenza
bird
flu
strain
highli
pathogen
avian
influenza
virus
entrench
among
poultri
part
asia
africa
middl
human
infect
virus
note
mani
countri
includ
indonesia
three
cluster
eastern
indonesia
human
case
highli
pathogen
avian
influenza
one
highest
rate
transmiss
avian
influenza
rather
probabl
link
explain
differ
receptor
specif
avian
receptor
prefer
linkag
wherea
human
prefer
linkag
product
infect
may
difficulti
jump
one
host
avian
human
oseltamivir
consid
golden
grail
stockpil
use
need
prevail
first
treat
infect
individu
moder
diseas
sever
second
protect
famili
member
index
case
interrupt
transmiss
third
peopl
area
surround
index
case
ring
prophylaxi
administ
oral
oseltamivir
fig
drug
choic
therapi
season
avian
zanamivir
fig
inhal
via
rather
sophist
devid
rank
second
wait
still
hypothet
avian
influenza
pandem
world
recent
confront
new
influenza
first
call
pig
mexican
variant
spread
rapidli
five
contin
thu
epidemiolog
term
gave
rise
pandem
although
highli
contagi
mexican
influenza
variant
far
proven
pathogen
season
influenza
variant
although
start
journey
variant
mexican
viru
normal
sensit
nai
oseltamivir
zanamivir
howev
worri
phenomenon
observ
within
past
year
widespread
oseltamivir
resist
influenza
unit
south
suggest
mutat
confer
resist
oseltamivir
leav
influenza
viru
sever
howev
viru
pathogen
fatal
immunocompromis
contrari
oseltamivir
allow
complet
recoveri
transplant
recipi
influenza
viru
infect
respond
influenza
viru
strain
resist
nai
zanamivir
oseltamivir
would
circul
stabl
low
level
sinc
compound
introduc
clinic
influenza
b
virus
reduc
sensit
nai
may
also
aris
frequent
influenza
origin
point
peter
pales
influenza
may
effect
transmit
among
guinea
pig
person
commun
intern
symposium
neurovirolog
san
diego
california
usa
novemb
effect
demonstr
bouvier
et
al
influenza
open
new
avenu
studi
transmiss
influenza
viru
infect
also
chemotherapi
chemoprophylaxi
infect
although
resist
oseltamivir
also
note
influenza
viru
ie
due
delet
four
amino
acid
resist
oseltamivir
would
emerg
higher
rate
influenza
viru
influenza
viru
influenza
b
viru
influenza
viru
might
signific
natur
variat
sensit
although
reduc
sensit
influenza
oseltamivir
note
sever
influenza
virus
ie
carri
mutat
may
retain
high
pathogen
viru
vitro
vivo
mice
learn
ferret
advis
increas
dose
oseltamivir
treat
highli
pathogen
avian
influenza
infect
novel
neuraminidas
mutat
describ
show
resist
oseltamivir
zanamivir
clinic
relev
resist
mutat
remain
elucid
take
togeth
resist
mutat
collect
oseltamivir
skehel
colleagu
consid
prudent
pandem
stockpil
oseltamivir
augment
addit
antivir
drug
includ
stockpil
oseltamivir
tamiflu
precautionari
measur
influenza
pandem
riski
costli
recomfort
therefor
intens
effort
made
improv
synthesi
oseltamivir
start
materi
shikim
acid
normal
obtain
chines
star
effort
inde
allow
practic
time
synthesi
environment
issu
link
chemic
stabil
oseltamivir
would
easili
remov
degrad
normal
sewag
point
stabil
compound
also
propens
contribut
viru
drug
resist
new
nai
forthcom
may
supersed
classic
nai
oseltamivir
zanamivir
fig
certainli
seem
promis
activ
influenza
viru
mutant
prodrug
would
compar
activ
oseltamivir
immunocompet
murin
model
influenza
viru
potent
inhibitori
activ
influenza
virus
subtyp
addit
zanamivir
oseltamivir
peramivir
also
fig
show
high
promis
viru
agent
latter
demonstr
viru
mechan
develop
resist
oseltamivir
fig
propos
paradigmat
correct
nai
inhibitor
whether
zanamivir
oseltamivir
peramivir
still
tri
find
best
way
applic
would
inject
peramivir
offer
ideal
final
solut
viru
remain
import
factor
nai
mani
year
design
synthesi
relationship
sar
studi
continu
tri
cope
primordi
import
avian
influenza
viru
influenza
viru
mexican
variant
becom
pandem
threat
human
prepar
alreadi
suppos
mani
year
combin
oseltamivir
exampl
doubl
combin
amantadin
oseltamivir
may
rank
among
variou
measur
could
taken
curb
influenza
viru
infect
review
perspect
chemotherapi
rsv
time
ribavirin
given
aerosol
mgml
antivir
agent
approv
treatment
rsv
infect
sever
new
possibl
drug
candid
happen
ribavirin
drug
candid
chemotherapi
rsv
infect
look
like
nowaday
human
rsv
major
caus
upper
lower
respiratori
tract
infect
pediatr
popul
infect
particularli
problemat
infant
born
prematur
congenit
heart
diseas
chronic
lung
diseas
cld
otherwis
immun
compromis
refer
therein
elderli
immunocompromis
adult
also
increas
risk
develop
complic
even
death
associ
rsv
infect
review
see
falsey
ribavirin
still
antivir
agent
approv
treatment
rsv
infect
due
efficaci
toxic
issu
limit
inhal
nebul
ribavirin
remain
standard
therapi
treatment
rsv
infect
despit
costli
cumbersom
pelaez
et
recent
point
efficaci
oral
ribavirin
treatment
lower
respiratori
tract
infect
lung
transplant
argu
studi
conduct
compar
efficaci
oral
ribavirin
vs
nebul
therapi
rsv
year
research
approv
vaccin
prophylact
therapi
avail
polyclon
rsv
palivizumab
human
monoclon
antibodi
target
rsv
fusion
effect
treatment
administ
pediatr
patient
clear
need
new
therapeut
improv
efficaci
safeti
broader
applic
review
see
meanwel
rsv
encod
three
surfac
glycoprotein
fusion
protein
f
attach
glycoprotein
g
small
hydrophob
protein
sh
f
g
glycoprotein
requir
effici
infect
vivo
f
protein
alon
suffici
viru
bind
entri
cell
rsv
major
caus
hospit
preterm
infant
infant
prophylaxi
palivizumab
significantli
reduc
incid
hospit
rel
placebo
gener
well
toler
infant
age
year
includ
prematur
bronchopulmonari
dysplasiacld
hemodynam
signific
congenit
heart
diseas
risk
factor
earli
seriou
rsv
infect
palivizumab
approv
use
children
experi
rsv
lower
respiratori
tract
infect
earli
life
high
rate
subsequ
recurr
wheez
palivizumab
amelior
prevent
lower
respiratori
tract
infect
preterm
infant
may
reduc
subsequ
recurr
wu
et
describ
select
antibodi
prevent
rsv
infect
appli
iter
mutagenesi
approach
abl
identifi
palivizumab
fab
variant
improv
palivizumab
igg
variant
improv
abil
neutral
rsv
recent
new
antibodi
motavizumab
develop
prevent
rsv
motavizumab
bind
rsv
f
protein
better
palivizumab
reduc
pulmonari
rsv
titer
lower
level
palivizumab
motavizumab
current
evalu
pivot
clinic
trial
rsv
prophylaxi
reduct
asthma
experiment
concern
origin
preclin
studi
cotton
rat
rsv
escap
mutant
may
emerg
immunosuppress
patient
palivizumab
aris
human
palivizumab
may
obvious
zhao
evalu
potenti
rsv
mutant
aris
vivo
cotton
rat
immunosuppress
cyclophosphamid
three
five
anim
mix
popul
lung
viru
clone
three
anim
reveal
f
gene
mutat
associ
resist
palivizumab
thu
prolong
pulmonari
replic
rsv
presenc
palivizumab
follow
appear
virus
resist
palivizumab
use
rna
interfer
rnai
approach
inhibit
rsv
parainfluenza
viru
achiev
mous
intranas
administ
short
interf
rna
sirna
similar
success
obtain
intranas
sirna
nanoparticl
target
viral
gene
initi
clinic
studi
safeti
toler
pharmacokinet
favor
pursuit
sirna
ie
rsv
similarli
sirna
deoxyribozym
dna
zyme
potenti
present
therapeut
prophylact
approach
rsv
diseas
activ
base
abil
bind
cleav
complementari
rna
sequenc
thu
inhibit
protein
express
exampl
deoxyribozym
target
conserv
genom
rna
sequenc
rsv
nucleocapsid
protein
shown
block
rsv
infect
sidwel
recent
review
prospect
princip
drug
candid
control
rsv
infect
promin
among
cite
compound
latter
compound
becam
later
known
fig
two
rsv
fusion
inhibitor
fig
fig
target
glycoprotein
could
deduc
resist
mutat
select
fig
fig
first
report
dc
pevear
viropharma
mention
wyde
et
evalu
cihlar
found
target
f
protein
rsv
efficaci
rsv
demonstr
vitro
vivo
cotton
rat
follow
deliveri
small
droplet
accord
sidwel
compound
phase
trial
decis
develop
part
due
development
cost
origin
name
first
time
report
andri
colleagu
structur
amino
fig
fundament
differ
nevertheless
target
f
protein
fig
highli
potent
nm
accord
limit
oral
bioavail
like
found
protect
cotton
rat
experiment
rsv
methyl
anoth
exampl
agent
target
f
confirm
mechan
action
inhibit
fusion
viru
mutant
select
resist
vitro
found
refractori
vivo
prove
oral
efficaci
rsv
infect
balbc
mice
cotton
numer
structur
variant
like
still
excel
potenc
oral
bioavail
powel
colleagu
recent
identifi
new
class
rsv
inhibitor
name
eventu
led
identif
fig
clinic
consid
truli
novel
inhibitor
rsv
replic
benzodiazinylurea
deriv
target
nucleocapsid
unlik
f
protein
inhibitor
see
supra
activ
rsv
infect
conclus
latter
paper
hail
promis
candid
date
treatment
rsv
diseas
human
wake
data
vivo
efficaci
oral
bioavail
sound
dare
statement
follow
work
beauchamp
et
al
seri
acyclovir
deriv
modif
heterocycl
base
yield
significantli
activ
compound
bozenna
golankiewicz
jerzi
boryski
start
new
program
around
new
acyclovir
deriv
one
nitrogen
center
block
methyl
incorpor
addit
ring
structur
mark
activ
herp
simplex
viru
compar
acyclovir
obtain
methyl
guanin
methyl
fig
compound
respect
origin
public
boryski
et
methyl
allow
antivir
activ
acyclovir
preserv
virtual
abolish
follow
earliest
report
deriv
guanin
sattsangi
et
success
implement
acyclovir
also
ganciclovir
result
tricycl
analogu
ganciclovir
compound
origin
public
fig
prove
markedli
activ
also
viru
vzv
cytomegaloviru
substitut
methyl
group
moieti
phenyl
group
tricycl
acyclovir
tricycl
ganciclovir
fig
compound
origin
give
rise
fluoresc
antivir
compound
one
hand
show
antivir
activ
profil
similar
parent
compound
acyclovir
ganciclovir
hand
show
rel
strong
fluoresc
make
use
noninvas
diagnosi
herpesviru
line
research
extend
compound
origin
public
fluoresc
tricycl
analogu
acyclovir
yet
extens
chain
tacv
tgcv
yield
phenoxycarbonyloxi
phenyl
substitut
deriv
compound
origin
public
fig
combin
high
antiherpet
activ
strong
fluoresc
similarli
substitut
tacv
tgcv
deriv
show
high
select
togeth
fluoresc
introduct
fluorin
ie
part
structur
may
make
tricycl
acyclovir
ganciclovir
analogu
amen
nmr
meanwhil
fluoresc
tricycl
acyclovir
ganciclovir
deriv
demonstr
pronounc
cytostat
activ
accompani
pronounc
bystand
effect
thymidin
kinas
tk
tumor
cell
import
particular
observ
view
context
earlier
observ
tumor
cell
transform
tk
gene
becom
highli
sensit
cytostat
effect
drug
culver
et
al
report
rat
bear
glioma
tumor
could
success
treat
ganciclovir
follow
situ
transfect
tk
combin
genechemotherapi
approach
cancer
elabor
et
fluoresc
tricycl
acyclovir
ganciclovir
may
well
fit
approach
fluoresc
could
readili
monitor
biolog
fluid
tissu
lipophil
acyclovir
ganciclovir
may
better
taken
blood
central
nervou
follow
acyclovir
ganciclovir
rel
unknown
hydroxymethyl
methylguanin
especi
enantiom
serv
start
point
implant
bridg
although
quit
unfortun
pursu
antivir
drug
candid
credenti
known
sinc
late
person
alway
emphas
potenti
antivir
therefor
favor
use
scaffold
build
tricycl
analogu
reminisc
tricycl
deriv
acyclovir
tacv
ganciclovir
tgcv
see
supra
tricycl
analogu
report
ostrowski
et
confirm
potenti
approach
prevail
also
concept
tricycl
acyclovir
ganciclovir
approach
activ
vzv
could
easili
extend
number
deriv
includ
deriv
fig
ago
must
met
dr
maria
preobrazhenskaya
went
trip
remot
campu
kortrijk
side
visit
still
gaus
institut
new
antibiot
russian
academi
medic
scienc
moscow
russia
decid
work
antibiot
antibacteri
agent
cytostat
agent
origin
collabor
result
sever
paper
describ
cytostat
activ
number
anthracyclin
ie
daunorubicin
well
streptonigrin
incident
ferenc
sztaricskai
see
infra
latter
paper
none
compound
deriv
explor
antivir
potenti
antibiot
yet
antibiot
belong
class
compound
arcyriaflavin
report
exhibit
potent
select
inhibit
human
cytomegaloviru
hcmv
bisindolylmaleimid
arcyriaflavin
fig
may
even
potenti
use
c
viru
mean
time
novel
deriv
antibiot
novel
report
although
consid
cytostat
regret
potenti
antivir
agent
yet
glycopeptid
antibiot
vancomycin
fig
eremomycin
ristocetin
teicoplanin
aglycon
nonglycosyl
part
serv
start
point
synthesi
semisynthet
deriv
antivir
activ
ie
compound
teicoplanin
type
aglycon
fig
exhibit
mode
action
glycopeptid
antibiot
could
ascrib
inhibit
viral
entri
work
along
line
eman
sever
glycopeptid
deriv
inact
bacteria
prove
quit
effect
select
antiretrovir
agent
ie
compound
fig
compound
lost
antibacteri
activ
ie
abil
interact
peptidoglycan
glycopeptidyl
transferas
may
expect
lead
bacteri
resist
even
prolong
administr
glycopeptid
aglycon
deriv
may
therefor
consid
promis
candid
drug
chemotherapi
hiv
infect
numer
glycopeptid
antibiot
primarili
deriv
eremomycin
teicoplanin
describ
antibacteri
shown
earlier
regard
mani
compound
also
show
activ
coronavirus
felin
infecti
periton
viru
fipv
human
sar
cov
ie
compound
fpiv
sar
cov
compound
fipv
sar
cov
fig
although
mode
action
could
like
mode
action
attribut
inhibit
viral
entri
process
gener
close
correl
valu
compound
fipv
sar
whether
mention
glycopeptid
aglycon
deriv
would
viru
activ
known
probabl
never
assess
therefor
came
surpris
one
particular
glycopeptid
aglycon
deriv
name
aglycoristocetin
cyclobuten
dion
carri
hydrophob
side
chain
fig
compound
origin
public
show
specif
consist
select
activ
variou
influenza
b
mode
action
compound
assum
associ
influenza
viru
entri
signal
mani
glycopeptid
antibiot
deriv
report
maria
peobrazhenskaya
revisit
potenti
viru
activ
vice
versa
compound
ferenc
sztaricskai
cowork
also
look
potenti
activ
hiv
sar
cov
sinc
graciela
andrei
robert
snoeck
michel
vandeputt
describ
inhibitori
effect
acycl
nucleosid
phosphon
cidofovir
vitro
replic
cidofovir
use
anecdot
success
treatment
variou
diseas
associ
polyomavirus
jc
progress
multifoc
leukoencephalopathi
pml
bk
hemorrhag
cystiti
hc
bk
viru
nephropathi
bkn
review
clinic
data
obtain
cidofovir
treatment
polyomaviru
jc
bk
pml
hc
address
case
report
appear
within
past
period
potenti
use
cidofovir
treatment
infect
remark
report
perhap
dual
infect
polyomaviru
bk
herp
simplex
viru
hsv
hematopoiet
stem
cell
transplant
hsct
recipi
success
treat
cidofovir
intraven
dose
mgkg
weekli
three
time
everi
week
three
addit
time
cidofovir
may
preferenti
inhibit
hsv
well
hcmv
infect
could
ration
basi
specif
inhibitori
effect
viral
dna
polyomavirus
induc
dna
polymeras
make
difficult
explain
favor
result
report
cidofovir
treatment
polymaviru
bk
viru
review
rinaldo
incident
latter
review
structur
cidofovir
correctli
present
mechan
action
cidofovir
would
inhibit
polyomaviru
bk
replic
human
renal
tubular
cell
transcript
late
viral
mrna
downstream
viral
earli
gene
esterif
cidofovir
ether
lipid
group
hexadecyloxopropyl
octadecyloxyethyl
oleyloxyethyl
would
enhanc
vitro
inhibitori
effect
cidofovir
polyomaviru
bk
replic
bkn
import
caus
renal
graft
dysfunct
kidney
transplant
recipi
bk
viru
first
identifi
kidney
transplant
patient
ureter
bk
viru
found
normal
healthi
kidney
reactiv
transplant
kidney
consequ
immunosuppress
ie
tacrolimu
mycophenol
mofetil
prednisolon
may
caus
interstiti
nephriti
nephropathi
may
lead
irrevers
graft
polyomaviru
consid
hot
problem
renal
cidofovir
highli
concentr
tubuli
renal
tissu
primari
site
bk
viru
infect
proven
benefici
effect
bkn
even
administ
weekli
low
dose
mgkg
intraven
similarli
favor
result
obtain
cidofovir
review
bonvoisin
et
also
includ
first
case
japan
kidney
transplant
recipi
success
treat
cidofovir
follow
random
control
studi
prospect
evalu
effect
cidofovir
graft
surviv
well
bk
viral
cidofovir
weekli
mgkg
intraven
also
proven
success
treatment
bk
hc
recipi
observ
necessit
followup
prospect
trial
treatment
hc
allogen
stem
cell
transplant
cidofovir
may
even
instil
directli
bladder
regimen
shown
decreas
bk
viral
load
significantli
improv
clinic
whether
cidofovir
addit
highli
activ
therapi
haart
would
give
addit
benefit
compar
haart
alon
treatment
pml
patient
could
use
cidofovir
treatment
pml
continu
controversi
sinc
previou
review
cidofovir
would
help
treatment
pml
accord
accord
favor
respons
pml
visual
magnet
reson
imag
brain
treatment
cidofovir
mgkg
everi
week
combin
cytarabin
mgkgday
day
everi
week
illustr
figur
case
obviou
regress
lesion
thymidin
phosphorylas
tpase
one
key
enzym
involv
salvag
catabol
pyrimidin
tpase
catalyz
revers
phosphorolysi
format
thymin
fig
tpase
recogn
substrat
also
varieti
analogu
includ
bvdu
brivudin
bvdu
mean
time
licens
sever
european
countri
treatment
herp
zoster
prove
efficaci
singl
oral
dose
mg
daili
day
see
fact
tpase
convert
bvdu
free
base
bvu
bvu
inhibitor
dpd
dihydropyrimidin
dehydrogenas
enzym
respons
hydrogen
antitumor
agent
fu
shown
enhanc
toxic
fu
combin
bvdu
tpase
inhibitor
see
infra
prevent
degrad
bvu
principl
enhanc
antivir
activ
bvdu
concomitantli
therewith
reduc
toxic
side
effect
fu
latter
prodrug
thereof
use
inadvert
combin
bvdu
despit
attract
potenti
increas
antivir
activ
bvdu
idu
tft
see
tpase
inhibitor
see
infra
fulli
explor
adjunct
antivir
agent
instead
becom
clear
tpase
ident
endotheli
cell
growth
factor
factor
known
sinc
mid
sole
angiogen
factor
present
interest
tpase
inhibitor
shift
toward
potenti
anticanc
agent
block
angiogenesi
review
tpase
overexpress
mani
solid
tumor
includ
breast
ovarian
colorect
pancreat
cancer
point
role
enzym
tumor
vascular
compound
report
tpase
inhibitor
first
one
date
long
tpase
recogn
angiogen
factor
must
fig
describ
peter
langen
took
fig
could
view
uracil
deriv
ring
closur
describ
tpase
new
approach
base
multisubstr
inhibitor
tpase
multisubstr
concept
base
upon
howev
follow
except
studi
novel
uracil
deriv
describ
tpase
inhibitor
properti
includ
aeac
fig
one
promis
tpase
inhibitor
describ
inhibitori
effect
angiogenesi
thymidin
phosphorylas
inhibitor
tpi
methyl
uracil
hydrochlorid
fig
characterist
compound
potenti
antitumor
activ
idu
light
explain
would
farfetch
postul
tpi
may
potenti
antivir
activ
idu
tft
bvdu
well
acycl
nucleosid
phosphon
cidofovir
adefovir
also
refer
phosphonomethoxyalkyl
analogu
gain
wide
notorieti
would
almost
seem
odd
least
would
activ
tpase
inde
substanti
inhibit
lymphoma
observ
seri
phosphonomethoxyalkyl
thymin
order
decreas
activ
r
r
r
inhibit
releas
endotheli
cell
may
repres
potenti
target
r
fig
follow
tpase
inhibitor
activ
particular
anticanc
activ
gener
revers
transcriptas
rt
nucleosid
type
ie
tpi
nucleotid
type
ie
r
tpase
inhibitor
describ
analog
extend
type
tpase
inhibitor
fig
like
rt
inhibitor
nnrti
inhibit
tpase
via
mechan
thu
act
alloster
inhibitor
recent
would
fit
caviti
aspart
acid
residu
critic
locat
distanc
site
tpase
ten
stori
subject
present
review
offer
mix
premis
promis
done
period
span
one
two
decad
like
continu
next
year
ata
analogu
continu
find
new
applic
one
last
influenza
viru
given
lack
specif
would
ever
find
final
nich
adam
origin
ata
still
look
upon
nnrti
genuin
nnrti
nevirapin
efavirenz
etravirin
rilpivirin
other
may
yet
uncov
side
effect
worth
pursu
among
hiv
ini
raltegravir
first
cross
finish
line
therebi
fulfil
premis
elvitegravir
second
cross
line
prospect
quadrupl
drug
combin
consist
tenofovir
emtricitabin
elvitegravir
booster
pharmacoenhanc
aftermath
ini
ledgf
may
consid
fascin
riski
target
develop
ledgf
inhibitor
may
roller
coaster
ride
present
talk
write
influenza
viru
strain
resist
oseltamivir
immin
avian
influenza
pandem
meanwhil
influenza
mexican
pandem
swept
five
contin
oseltamivir
stockpil
synthesi
improv
still
first
choic
drug
use
need
curb
influenza
pandem
whether
meantim
rsv
remain
real
threat
least
young
old
besid
monoclon
antibodi
palivizumab
question
use
ribavirin
still
wait
effect
versatil
agent
pure
chemic
viewpoint
surpris
tricycl
guanosin
deriv
base
receiv
littl
attent
biomed
world
despit
uniqu
combin
activ
combin
mark
fluoresc
properti
antibiot
antivir
often
envisag
antipod
reconcil
demonstr
glycopeptid
antibiot
aglycon
abl
block
entri
envelop
virus
hiv
uniqu
properti
may
well
extend
explor
envelop
virus
coronavirus
alreadi
done
myxovirus
bare
touch
upon
herpesvirus
even
yet
consid
cidofovir
acycl
nucleosid
phosphon
yet
unexplor
potenti
treatment
call
papovavirus
potenti
treatment
hpv
infect
alreadi
equal
promis
potenti
treatment
polyomaviru
infect
explor
well
tpase
target
increas
antivir
activ
compound
like
bvdu
vzv
readili
degrad
dthd
phosphorylas
deserv
much
attent
receiv
far
right
dthd
phosphorylas
consid
target
antitumor
agent
given
angiogen
prowess
thu
offer
design
compound
antitumor
potenti
erik
de
clercq
md
phd
chairman
depart
microbiolog
immunolog
medic
school
katholiek
universiteit
leuven
kuleuven
well
chairman
board
rega
institut
medic
research
septemb
current
presid
rega
foundat
director
belgian
flemish
royal
academi
medicin
member
academia
europaea
fellow
american
associ
advanc
scienc
also
titular
prof
p
de
somer
chair
microbiolog
teach
cours
cell
biolog
biochemistri
microbiolog
kuleuven
kortrijk
medic
school
septemb
still
allow
teach
part
biochemistri
cours
kuleuven
campu
kortrijk
professor
de
clercq
receiv
hoechst
marion
roussel
call
aventi
award
american
societi
microbiolog
maisin
prize
biomed
scienc
nation
scienc
foundat
belgium
pioneer
effort
field
antivir
research
honorari
doctor
sever
univers
ie
ghent
belgium
athen
greec
ferrara
itali
shandong
jinan
china
charl
univers
pragu
czech
republ
budejovic
czech
republ
elect
european
inventor
year
life
time
achiev
award
european
union
scientif
interest
antivir
chemotherapi
field
particular
develop
new
antivir
agent
variou
viral
infect
includ
herp
simplex
viru
hsv
viru
vzv
cytomegaloviru
cmv
human
immunodefici
viru
hiv
hepat
b
viru
hbv
human
papilloma
viru
hpv
hepat
c
viru
hcv
co
number
antivir
drug
current
use
treatment
hsv
infect
valaciclovir
vzv
infect
brivudin
cmv
infect
cidofovir
hbv
infect
adefovir
dipivoxil
hiv
infect
aid
tenofovir
disoproxil
fumar
market
combin
emtricitabin
combin
emtricitabin
efavirenz
also
approv
treatment
hbv
infect
chronic
hepat
b
